Scholarlink

<p>Lipid-lowering therapy (LLT) with statins is effective for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults aged &gt; 75 years, but comprehensive evidence on their efficacy and safety for primary prevention in the elderly is limited. An individualised, shared decision-making approach is recommended with LLT in the elderly for primary ASCVD prevention, using assessment tools to estimate the patient’s cardiovascular risk and taking into consideration factors such as the risk of treatment-related adverse events and potential drug-drug interactions. Ongoing clinical trials will help guide the use of lipid-lowering therapies in the elderly.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Take an individualised approach with lipid-lowering therapy in the elderly

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Amy Zhuang-Yan

摘要

Lipid-lowering therapy (LLT) with statins is effective for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults aged > 75 years, but comprehensive evidence on their efficacy and safety for primary prevention in the elderly is limited. An individualised, shared decision-making approach is recommended with LLT in the elderly for primary ASCVD prevention, using assessment tools to estimate the patient’s cardiovascular risk and taking into consideration factors such as the risk of treatment-related adverse events and potential drug-drug interactions. Ongoing clinical trials will help guide the use of lipid-lowering therapies in the elderly.